CGAS and metabolic dysfunction-associated steatotic liver disease: In addition to its association with hepatitis B and liver cancer, the cGAS–STING signaling pathway has been shown to be activated in alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and liver fibrosis.